Serum proteomic profiling in patients with bladder cancer.
about
Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.From proteomic multimarker profiling to interesting proteins: thymosin-β(4) and kininogen-1 as new potential biomarkers for inflammatory hepatic lesions.Serum peptidome profiling in patients with gastric cancer.Biomarkers discovery by peptide and protein profiling in biological fluids based on functionalized magnetic beads purification and mass spectrometry.Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer.Comparison of plasma from healthy nonsmokers, smokers, and lung cancer patients: pattern-based differentiation profiling of low molecular weight proteins and peptides by magnetic bead technology with MALDI-TOF MS.Identification of novel low molecular weight serum peptidome biomarkers for non-small cell lung cancer (NSCLC).Serum proteomic profiling for the early diagnosis of colorectal cancer.Magnetic bead-based salivary peptidome profiling for periodontal-orthodontic treatment.Diagnostic model of saliva peptide finger print analysis of primary Sjögren's syndrome patients by using weak cation exchange magnetic beadsSerum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.Bladder cancer determination via two urinary metabolites: a biomarker pattern approachIdentification of peptide regions of SERPINA1 and ENOSF1 and their protein expression as potential serum biomarkers for gastric cancer.Diagnostic model of saliva peptide finger print analysis of oral squamous cell carcinoma patients using weak cation exchange magnetic beads.Proteomic study of benign and malignant pleural effusion.[Preliminary Study of Differentially Expressed Serum Peptides of Advanced NSCLC Patients Responsive to EGFR-TKI and Their Clinical Significance].The impact of advanced proteomics in the search for markers and therapeutic targets of bladder cancer.Bladder cancer detection and monitoring: assessment of urine- and blood-based marker testsSerum peptidomic biomarkers for pulmonary metastatic melanoma identified by means of a nanopore-based assay.A multiplex biomarker approach for the diagnosis of transitional cell carcinoma from canine urine.Circulating Biomarkers in Bladder Cancer.Methods for the discovery of low-abundance biomarkers for urinary bladder cancer in biological fluids.Tissue and serum proteomic profiling for diagnostic and prognostic bladder cancer biomarkers.Proteome research in urothelial carcinoma.Developing proteomic biomarkers for bladder cancer: towards clinical application.Eight-plex iTRAQ labeling and quantitative proteomic analysis for human bladder cancer.Intermediate and low abundant protein analysis of vitamin D deficient obese and non-obese subjects by MALDI-profiling.LC-MS-based serum metabolic profiling for genitourinary cancer classification and cancer type-specific biomarker discovery.
P2860
Q33778668-7177CC56-7646-48C5-9D6A-0B917FD4DD1FQ33874229-EC10A808-7B6D-4550-8C40-DD832EF93E3EQ33955495-1CFC4774-258A-4CFF-9772-5440E7F1E442Q33962458-F48442E2-2F41-4E1E-B4AD-5B94770B4246Q33976936-21877351-F1CA-43A6-B0FF-824AD8908293Q34166788-1EAC0BCB-D582-443D-971E-ADCD272127E6Q34281288-7286B670-852D-42D5-979B-FA488557A950Q34409534-E3852910-68C5-45E4-8C8F-C37B6CFD63B8Q34466902-CD931753-F3B6-4E68-8409-E0AED551924DQ34727360-985E9BAB-4D54-4386-8E60-5918CE1DF94AQ35034044-33953CEE-17F1-4EE7-B53E-993D445C13B7Q35497484-679029EF-4324-4B2A-8F6D-7E72C2B2EAD1Q35560299-C885125D-7517-419E-B399-E4258BA8EEFBQ35693688-9F887117-48AC-40A8-B7BA-57A5780923F6Q35946652-C806FBFE-755F-4C2D-8654-A73C485F2C1EQ36144126-74A86FFD-B3D6-40DF-BF28-0C567732C5DCQ36323508-EDF09A85-8DAA-4C37-BFE2-02B649ECE072Q36770389-8390784B-D0B9-4CFB-B1A6-2F98C6D116B8Q36893247-FFC49F79-AB5B-4C80-ABB7-0A6D61B25574Q36921097-3A9EF01B-9797-49CE-89F7-940440E19184Q37530401-7C346BAF-6B45-4AF1-A7F0-0F68A4553E8EQ37810251-F2AF61FD-8E19-4E48-8EA5-2F7BEEF5C1B0Q37818317-462B237B-E3D4-470C-99C2-508E484EAF1CQ38461516-AD0F4929-91C1-4500-B7AB-5BCD755B24E4Q38511509-5DF4C8C7-1128-45A8-84B4-A682E4C2A6B3Q41963590-C521AE29-F753-4847-A4AB-838DC7FA1D5FQ42282520-12E3A6BD-0329-485D-A3FC-E01E81AA47E9Q45715435-55222DD2-A168-404C-A200-ED4E7D3E5258
P2860
Serum proteomic profiling in patients with bladder cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Serum proteomic profiling in patients with bladder cancer.
@ast
Serum proteomic profiling in patients with bladder cancer.
@en
type
label
Serum proteomic profiling in patients with bladder cancer.
@ast
Serum proteomic profiling in patients with bladder cancer.
@en
prefLabel
Serum proteomic profiling in patients with bladder cancer.
@ast
Serum proteomic profiling in patients with bladder cancer.
@en
P2093
P1433
P1476
Serum proteomic profiling in patients with bladder cancer.
@en
P2093
Corinna Henkel
Gerhard Jakse
Joachim Grosse
Kristina Schwamborn
Nadine Reulen
René C Krieg
P304
P356
10.1016/J.EURURO.2009.02.031
P407
P577
2009-03-06T00:00:00Z